red-cherryred

Unlocking the benefits: MAP delivery utilising a JTM approach

Driving patient-centric, optimised and cost-effective post trial drug access.

Clinical trial sponsors, pharmaceutical and biotech companies, have an ethical and regulatory obligation to ensure that patients receive continued, post-trial access to treatments that have been identified as beneficial during a trial.

This webinar will introduce the traditional route many sponsors take when looking to uphold ethical obligations and continue post-trial treatment access, along with the unnecessary cost and complexity present in many scenarios.

After examining traditional approaches and their often incompatibility with optimised and cost-effective operations, Almac’s subject matter expert(s) will present the highly effective, yet under-utilised alternative: Managed Access Programmes underpinned by patient-centric, on-demand supply strategy.

Join us on Thursday 21 September at 3pm BST to discover how MAPs and Just in Time Manufacturing combined can empower you to better serve patients and meet ethical obligations, free up resource, optimise operations and maximise ROI. There will also be a live Q&A at the conclusion of the presentation.

Key Learning Objectives

Speakers

Speakers

Margaret Radford

Unlicensed Medicines Services Manager

Lynn McNeill

Supply Chain Solutions Manager JTM

Margaret Radford

Unlicensed Medicines Services Manager

As the Unlicensed Medicine Services Manager at Almac Clinical Services, Margaret leads a team of experienced personnel who are responsible for the onboarding and delivery of Managed Access Programmes at all Almac sites globally. Margaret has 20 years of professional experience within Project Management, Business Development, GMP Operations, and People Management.